The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.
NK cells and cancer: you can teach innate cells new tricks
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
RetractedCD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Müller, A., Pachynski, R., Czerwinski, D., Coutre, S., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301945 · Cited by 205
RetractedCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Self-citationInnate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824
Self-citationRosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
Braud, V. M., Allan, D. S. J., O'Callaghan, C. A., Söderström, K., D'Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., et al. (1998) · Nature · doi:10.1038/35869 · Cited by 2,227
Self-citationMiller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778
Up on the tightrope: natural killer cell activation and inhibition
Lanier, L. L. (2008) · Nature Immunology · doi:10.1038/ni1581 · Cited by 1,656
Self-citationWoo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
The biology of innate lymphoid cells
Artis, D., & Spits, H. (2015) · Nature · doi:10.1038/nature14189 · Cited by 1,634
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset
Cooper, M. A., Fehniger, T. A., Turner, S. C., Chen, K. S., Ghaheri, B. A., Ghayur, T., Carson, W. E., & Caligiuri, M. A. (2001) · Blood · doi:10.1182/blood.v97.10.3146 · Cited by 1,449
Perforin and granzymes: function, dysfunction and human pathology
Voskoboinik, I., Whisstock, J. C., & Trapani, J. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3839 · Cited by 1,327
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
Johnston, R. J., Comps-Agrar, L., Hackney, J., Yu, X., Huseni, M., Yang, Y., Park, S., Javinal, V., Chiu, H., Irving, B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.018 · Cited by 1,194
Imai, K., Matsuyama, S., Miyake, S., Suga, K., & Nakachi, K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03231-1 · Cited by 1,190
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083
HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A
Lee, N., Llano, M., Carretero, M., Ishitani, A., Navarro, F., López-Botet, M., & Geraghty, D. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5199 · Cited by 1,053
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy
Guerra, N., Tan, Y. X., Joncker, N. T., Choy, A., Gallardo, F., Xiong, N., Knoblaugh, S., Cado, D., Greenberg, N. R., & Raulet, D. H. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.016 · Cited by 850
Regulation of Ligands for the NKG2D Activating Receptor
Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W., & Jung, H. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095951 · Cited by 848
Properties of mouse and human IgG receptors and their contribution to disease models
Bruhns, P. (2012) · Blood · doi:10.1182/blood-2012-01-380121 · Cited by 847
Cytokine-induced memory-like natural killer cells
Cooper, M. A., Elliott, J. M., Keyel, P. A., Yang, L., Carrero, J. A., & Yokoyama, W. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813192106 · Cited by 831
Lopez-Vergès, S., Milush, J. M., Schwartz, B. S., Pando, M. J., Jarjoura, J., York, V. A., Houchins, J. P., Miller, S., Kang, S.-M., Norris, P. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110900108 · Cited by 822
Self-citationBenson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807
Pende, D., Parolini, S., Pessino, A., Sivori, S., Augugliaro, R., Morelli, L., Marcenaro, E., Accame, L., Malaspina, A., Biassoni, R., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1505 · Cited by 798
New aspects of natural-killer-cell surveillance and therapy of cancer
Smyth, M. J., Hayakawa, Y., Takeda, K., & Yagita, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc928 · Cited by 752
Activation of NK cell cytotoxicity
Smyth, M. J., Cretney, E., Kelly, J. M., Westwood, J. A., Street, S. E. A., Yagita, H., Takeda, K., Dommelen, S. L. H. V., Degli-Esposti, M. A., & Hayakawa, Y. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.034 · Cited by 714
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity
Spinner, M. A., Sanchez, L. A., Hsu, A. P., Shaw, P. A., Zerbe, C. S., Calvo, K. R., Arthur, D. C., Gu, W., Gould, C. M., Brewer, C. C., et al. (2014) · Blood · doi:10.1182/blood-2013-07-515528 · Cited by 712
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
Brandt, C. S., Baratin, M., Yi, E. C., Kennedy, J., Gao, Z., Fox, B., Haldeman, B., Ostrander, C. D., Kaifu, T., Chabannon, C., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090681 · Cited by 706
Imai, C., Iwamoto, S., & Campana, D. (2005) · Blood · doi:10.1182/blood-2004-12-4797 · Cited by 659
Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding
Salih, H. R., Rammensee, H.-G., & Steinle, A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4098 · Cited by 643
the Immunological Genome Consortium, Robinette, M. L., Fuchs, A., Cortez, V. S., Lee, J. S., Wang, Y., Durum, S. K., Gilfillan, S., & Colonna, M. (2015) · Nature Immunology · doi:10.1038/ni.3094 · Cited by 641
Cretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J. J., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1356 · Cited by 616
Cerwenka, A., Baron, J. L., & Lanier, L. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201238598 · Cited by 606
Self-citationNKG2D Receptor and Its Ligands in Host Defense
Lanier, L. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0098 · Cited by 599
Self-citationPessino, A., Sivori, S., Bottino, C., Malaspina, A., Morelli, L., Moretta, L., Biassoni, R., & Moretta, A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.5.953 · Cited by 579
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
Ndhlovu, L. C., Lopez-Vergès, S., Barbour, J. D., Jones, R. B., Jha, A. R., Long, B. R., Schoeffler, E. C., Fujita, T., Nixon, D. F., & Lanier, L. L. (2012) · Blood · doi:10.1182/blood-2011-11-392951 · Cited by 514
Self-citationNatural killer cell deficiency
Orange, J. S. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.020 · Cited by 504
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
Chan, C. J., Martinet, L., Gilfillan, S., Souza-Fonseca-Guimaraes, F., Chow, M. T., Town, L., Ritchie, D. S., Colonna, M., Andrews, D. M., & Smyth, M. J. (2014) · Nature Immunology · doi:10.1038/ni.2850 · Cited by 492
Effect of NKG2D ligand expression on host immune responses
Champsaur, M., & Lanier, L. L. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2010.00893.x · Cited by 488
Self-citationBalancing natural killer cell activation through paired receptors
Martinet, L., & Smyth, M. J. (2015) · Nature Reviews Immunology · doi:10.1038/nri3799 · Cited by 485
Vance, R. E., Kraft, J. R., Altman, J. D., Jensen, P. E., & Raulet, D. H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.10.1841 · Cited by 482
Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46
Walzer, T., Bléry, M., Chaix, J., Fuseri, N., Chasson, L., Robbins, S. H., Jaeger, S., André, P., Gauthier, L., Daniel, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609692104 · Cited by 476
Kopp, H.-G., Placke, T., & Salih, H. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2123 · Cited by 469
Boyerinas, B., Jochems, C., Fantini, M., Heery, C. R., Gulley, J. L., Tsang, K. Y., & Schlom, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0059 · Cited by 468
Oppenheim, D. E., Roberts, S. J., Clarke, S. L., Filler, R., Lewis, J. M., Tigelaar, R. E., Girardi, M., & Hayday, A. C. (2005) · Nature Immunology · doi:10.1038/ni1239 · Cited by 454
Cantoni, C., Bottino, C., Vitale, M., Pessino, A., Augugliaro, R., Malaspina, A., Parolini, S., Moretta, L., Moretta, A., & Biassoni, R. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.5.787 · Cited by 452
Lazetic, S., Chang, C., Houchins, J. P., Lanier, L. L., & Phillips, J. H. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.4741 · Cited by 447
Self-citationChu, J., Deng, Y., Benson, D. M., He, S., Hughes, T., Zhang, J., Peng, Y., Mao, H., Yi, L., Ghoshal, K., et al. (2014) · Leukemia · doi:10.1038/leu.2013.279 · Cited by 439
Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice
Bix, M., Liao, N.-S., Zijlstra, M., Loring, J., Jaenisch, R., & Raulet, D. (1991) · Nature · doi:10.1038/349329a0 · Cited by 431
Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors
Ni, J., Miller, M., Stojanovic, A., Garbi, N., & Cerwenka, A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120944 · Cited by 419
Romagné, F., André, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., Capanni, M., Ruggeri, L., Benson, D. M., Blaser, B. W., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206532 · Cited by 408
NKG2D ligands in tumor immunity
Nausch, N., & Cerwenka, A. (2008) · Oncogene · doi:10.1038/onc.2008.272 · Cited by 408
Interleukin-10 and the immune response against cancer: a counterpoint
Mocellin, S., Marincola, F. M., & Young, H. A. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0705358 · Cited by 402
Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands
Kaiser, B. K., Yim, D., Chow, I.-T., Gonzalez, S., Dai, Z., Mann, H. H., Strong, R. K., Groh, V., & Spies, T. (2007) · Nature · doi:10.1038/nature05768 · Cited by 377
Role of NK cells in the control of metastatic spread and growth of tumor cells in mice
Gorelik, E., Wiltrout, R. H., Okumura, K., Habu, S., & Herberman, R. B. (1982) · International Journal of Cancer · doi:10.1002/ijc.2910300118 · Cited by 366
Gilfillan, S., Chan, C. J., Cella, M., Haynes, N. M., Rapaport, A. S., Boles, K. S., Andrews, D. M., Smyth, M. J., & Colonna, M. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081752 · Cited by 361
Cancer immunoediting by the innate immune system in the absence of adaptive immunity
O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C. M., Arthur, C., White, J. M., Uppaluri, R., Andrews, D. M., Ngiow, S. F., Teng, M. W. L., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112738 · Cited by 348
Schönfeld, K., Sahm, C., Zhang, C., Naundorf, S., Brendel, C., Odendahl, M., Nowakowska, P., Bönig, H., Köhl, U., Kloess, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.219 · Cited by 348
Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri, L., Capanni, M., Umansky, V., Paschen, A., Sucker, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36022 · Cited by 347
NKG2D function protects the host from tumor initiation
Smyth, M. J., Swann, J., Cretney, E., Zerafa, N., Yokoyama, W. M., & Hayakawa, Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050994 · Cited by 342
Han, J., Chu, J., Keung Chan, W., Zhang, J., Wang, Y., Cohen, J. B., Victor, A., Meisen, W. H., Kim, S.-H., Grandi, P., et al. (2015) · Scientific Reports · doi:10.1038/srep11483 · Cited by 340
Wu, J. D., Higgins, L. M., Steinle, A., Cosman, D., Haugk, K., & Plymate, S. R. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422206 · Cited by 330
Campbell, K. S., & Purdy, A. K. (2011) · Immunology · doi:10.1111/j.1365-2567.2010.03398.x · Cited by 329
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
Contardi, E., Palmisano, G. L., Tazzari, P. L., Martelli, A. M., Falà, F., Fabbi, M., Kato, T., Lucarelli, E., Donati, D., Polito, L., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21155 · Cited by 324
Pietra, G., Manzini, C., Rivara, S., Vitale, M., Cantoni, C., Petretto, A., Balsamo, M., Conte, R., Benelli, R., Minghelli, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2544 · Cited by 324
Gineau, L., Cognet, C., Kara, N., Lach, F. P., Dunne, J., Veturi, U., Picard, C., Trouillet, C., Eidenschenk, C., Aoufouchi, S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61014 · Cited by 307
Molecular definition of the identity and activation of natural killer cells
The Immunological Genome Project Consortium, Bezman, N. A., Kim, C. C., Sun, J. C., Min-Oo, G., Hendricks, D. W., Kamimura, Y., Best, J. A., Goldrath, A. W., & Lanier, L. L. (2012) · Nature Immunology · doi:10.1038/ni.2395 · Cited by 293
Self-citationAccelerated tumor growth in mice deficient in DNAM-1 receptor
Iguchi-Manaka, A., Kai, H., Yamashita, Y., Shibata, K., Tahara-Hanaoka, S., Honda, S.-I., Yasui, T., Kikutani, H., Shibuya, K., & Shibuya, A. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081611 · Cited by 290
Kohrt, H. E., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuseri, N., Bonnafous, C., Czerwinski, D., Rajapaksa, A., et al. (2014) · Blood · doi:10.1182/blood-2013-08-519199 · Cited by 283
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Vey, N., Bourhis, J.-H., Boissel, N., Bordessoule, D., Prebet, T., Charbonnier, A., Etienne, A., Andre, P., Romagne, F., Benson, D., et al. (2012) · Blood · doi:10.1182/blood-2012-06-437558 · Cited by 278
A new immunodeficiency disorder in humans involving NK cells
Roder, J. C., Haliotis, T., Klein, M., Korec, S., Jett, J. R., Ortaldo, J., Heberman, R. B., Katz, P., & Fauci, A. S. (1980) · Nature · doi:10.1038/284553a0 · Cited by 277
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
Ascierto, P. A., Simeone, E., Sznol, M., Fu, Y.-X., & Melero, I. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.008 · Cited by 276
Natural cytotoxicity receptors and their ligands
Kruse, P. H., Matta, J., Ugolini, S., & Vivier, E. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2013.98 · Cited by 273
Are natural killer cells superior CAR drivers?
Klingemann, H. (2014) · OncoImmunology · doi:10.4161/onci.28147 · Cited by 270
Jiang, H., Zhang, W., Shang, P., Zhang, H., Fu, W., Ye, F., Zeng, T., Huang, H., Zhang, X., Sun, W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.001 · Cited by 267
Uherek, C., Tonn, T., Uherek, B., Becker, S., Schnierle, B., Klingemann, H.-G., & Wels, W. (2002) · Blood · doi:10.1182/blood.v100.4.1265.h81602001265_1265_1273 · Cited by 262
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
Bartkowiak, T., & Curran, M. A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00117 · Cited by 256
A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection
Deng, W., Gowen, B. G., Zhang, L., Wang, L., Lau, S., Iannello, A., Xu, J., Rovis, T. L., Xiong, N., & Raulet, D. H. (2015) · Science · doi:10.1126/science.1258867 · Cited by 255
Müller, N., Michen, S., Tietze, S., Töpfer, K., Schulte, A., Lamszus, K., Schmitz, M., Schackert, G., Pastan, I., & Temme, A. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000082 · Cited by 253
DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Töpfer, K., Cartellieri, M., Michen, S., Wiedemuth, R., Müller, N., Lindemann, D., Bachmann, M., Füssel, M., Schackert, G., & Temme, A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1400330 · Cited by 249
Benson, D. M., Hofmeister, C. C., Padmanabhan, S., Suvannasankha, A., Jagannath, S., Abonour, R., Bakan, C., Andre, P., Efebera, Y., Tiollier, J., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438028 · Cited by 244
Deficient Natural Killer Cell Activity in X-Linked Lymphoproliferative Syndrome
Sullivan, J. L., Byron, K. S., Brewster, F. E., et al. (1980) · Science · doi:10.1126/science.6158759 · Cited by 243
Advantages and applications of CAR-expressing natural killer cells
Glienke, W., Esser, R., Priesner, C., Suerth, J. D., Schambach, A., Wels, W. S., Grez, M., Kloess, S., Arseniev, L., & Koehl, U. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00021 · Cited by 243
Hoskin, D., Mader, J., Furlong, S., Conrad, D., & Blay, J. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.3.527 · Cited by 242
Soluble MICA in malignant diseases
Holdenrieder, S., Stieber, P., Peterfi, A., Nagel, D., Steinle, A., & Salih, H. R. (2006) · International Journal of Cancer · doi:10.1002/ijc.21382 · Cited by 240
Shah, N. N., Baird, K., Delbrook, C. P., Fleisher, T. A., Kohler, M. E., Rampertaap, S., Lemberg, K., Hurley, C. K., Kleiner, D. E., Merchant, M. S., et al. (2015) · Blood · doi:10.1182/blood-2014-07-592881 · Cited by 238
Floros, T., & Tarhini, A. A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.015 · Cited by 229
Human NK cell lytic granules and regulation of their exocytosis
Krzewski, K., & Coligan, J. E. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00335 · Cited by 229
Triggering of Natural Killer Cells by the Costimulatory Molecule CD80 (B7-1)
Chambers, B. J., Salcedo, M., & Ljunggren, H.-G. (1996) · Immunity · doi:10.1016/s1074-7613(00)80257-5 · Cited by 227
Wiernik, A., Foley, B., Zhang, B., Verneris, M. R., Warlick, E., Gleason, M. K., Ross, J. A., Luo, X., Weisdorf, D. J., Walcheck, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0505 · Cited by 226
NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity
Albertsson, P. A., Basse, P. H., Hokland, M., Goldfarb, R. H., Nagelkerke, J. F., Nannmark, U., & Kuppen, P. J. K. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.09.007 · Cited by 226
NKG2D ligands as therapeutic targets.
(2013) · Europe PMC (PubMed Central) · Cited by 218
Role of Chemokines in the Biology of Natural Killer Cells
Maghazachi, A. A. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_20 · Cited by 216
Müller, T., Uherek, C., Maki, G., Chow, K. U., Schimpf, A., Klingemann, H.-G., Tonn, T., & Wels, W. S. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0383-3 · Cited by 212
Altvater, B., Landmeier, S., Pscherer, S., Temme, J., Schweer, K., Kailayangiri, S., Campana, D., Juergens, H., Pule, M., & Rossig, C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2810 · Cited by 206
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors
Alvarez-Breckenridge, C. A., Yu, J., Price, R., Wojton, J., Pradarelli, J., Mao, H., Wei, M., Wang, Y., He, S., Hardcastle, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.3013 · Cited by 205
Autologous natural killer cell therapy for human recurrent malignant glioma.
Ishikawa, E., Tsuboi, K., Saijo, K., Harada, H., Takano, S., Nose, T., & Ohno, T. (2004) · PubMed · Cited by 201
Boissel, L., Betancur, M., Lu, W., Krause, D., Van Etten, R., Wels, W., & Klingemann, H. (2013) · OncoImmunology · doi:10.4161/onci.26527 · Cited by 194
T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing
Kudo, K., Imai, C., Lorenzini, P., Kamiya, T., Kono, K., Davidoff, A. M., Chng, W. J., & Campana, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1365 · Cited by 191
Cytokine therapy reverses NK cell anergy in MHC-deficient tumors
Ardolino, M., Azimi, C. S., Iannello, A., Trevino, T. N., Horan, L., Zhang, L., Deng, W., Ring, A. M., Fischer, S., Garcia, K. C., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74337 · Cited by 191
Esser, R., Müller, T., Stefes, D., Kloess, S., Seidel, D., Gillies, S. D., Aperlo‐Iffland, C., Huston, J. S., Uherek, C., Schönfeld, K., et al. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01343.x · Cited by 188
Sahm, C., Schönfeld, K., & Wels, W. S. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1212-x · Cited by 186
Hayakawa, Y., Kelly, J. M., Westwood, J. A., Darcy, P. K., Diefenbach, A., Raulet, D., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5377 · Cited by 185
Benson, D. M., Cohen, A. D., Jagannath, S., Munshi, N. C., Spitzer, G., Hofmeister, C. C., Efebera, Y. A., Andre, P., Zerbib, R., & Caligiuri, M. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0304 · Cited by 180
Shimasaki, N., Fujisaki, H., Cho, D., Masselli, M., Lockey, T., Eldridge, P., Leung, W., & Campana, D. (2012) · Cytotherapy · doi:10.3109/14653249.2012.671519 · Cited by 177
Activation of Natural Killer Cells by Newcastle Disease Virus Hemagglutinin-Neuraminidase
Jarahian, M., Watzl, C., Fournier, P., Arnold, A., Djandji, D., Zahedi, S., Cerwenka, A., Paschen, A., Schirrmacher, V., & Momburg, F. (2009) · Journal of Virology · doi:10.1128/jvi.00211-09 · Cited by 177
Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
Melero, I., Hirschhorn-Cymerman, D., Morales-Kastresana, A., Sanmamed, M. F., & Wolchok, J. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2065 · Cited by 176
Recognition and Prevention of Tumor Metastasis by the NK Receptor NKp46/NCR1
Glasner, A., Ghadially, H., Gur, C., Stanietsky, N., Tsukerman, P., Enk, J., & Mandelboim, O. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102461 · Cited by 176
Stojanovic, A., Fiegler, N., Brunner-Weinzierl, M., & Cerwenka, A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302091 · Cited by 175
Crane, C. A., Austgen, K., Haberthur, K., Hofmann, C., Moyes, K. W., Avanesyan, L., Fong, L., Campbell, M. J., Cooper, S., Oakes, S. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413933111 · Cited by 174
Self-citationWilson, E. B., El-Jawhari, J. J., Neilson, A. L., Hall, G. D., Melcher, A. A., Meade, J. L., & Cook, G. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022842 · Cited by 174
Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity
Hermanson, D. L., & Kaufman, D. S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00195 · Cited by 172
Holt, D., Ma, X., Kundu, N., & Fulton, A. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1064-9 · Cited by 171
NK Cells Lyse T Regulatory Cells That Expand in Response to an Intracellular Pathogen
Roy, S., Barnes, P. F., Garg, A., Wu, S., Cosman, D., & Vankayalapati, R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1729 · Cited by 169
Differential Mechanisms of Shedding of the Glycosylphosphatidylinositol (GPI)-anchored NKG2D Ligands
Fernández‐Messina, L., Ashiru, O., Boutet, P., Agüera‐González, S., Skepper, J. N., Reyburn, H. T., & Valés‐Gómez, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.045906 · Cited by 167
Boissel, L., Betancur, M., Wels, W. S., Tuncer, H., & Klingemann, H. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.11.024 · Cited by 166
Hudspeth, K., Silva-Santos, B., & Mavilio, D. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00069 · Cited by 163
Laurent, S., Queirolo, P., Boero, S., Salvi, S., Piccioli, P., Boccardo, S., Minghelli, S., Morabito, A., Fontana, V., Pietra, G., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-108 · Cited by 163
Enhanced In Vivo Growth of Lymphoma Tumors in the Absence of the NK-Activating Receptor NKp46/NCR1
Halfteck, G. G., Elboim, M., Gur, C., Achdout, H., Ghadially, H., & Mandelboim, O. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801878 · Cited by 162
Reusch, U., Burkhardt, C., Fucek, I., Le Gall, F., Le Gall, M., Hoffmann, K., Knackmuss, S. H., Kiprijanov, S., Little, M., & Zhukovsky, E. A. (2014) · mAbs · doi:10.4161/mabs.28591 · Cited by 161
Matta, J., Baratin, M., Chiche, L., Forel, J.-M., Cognet, C., Thomas, G., Farnarier, C., Pipéroglou, C., Papazian, L., Chaussabel, D., et al. (2013) · Blood · doi:10.1182/blood-2013-01-481705 · Cited by 159
Release of MICB Molecules by Tumor Cells: Mechanism and Soluble MICB in Sera of Cancer Patients
Salih, H. R., Goehlsdorf, D., & Steinle, A. (2006) · Human Immunology · doi:10.1016/j.humimm.2006.02.008 · Cited by 157
Engineering anti‐GD2 monoclonal antibodies for cancer immunotherapy
Ahmed, M., & Cheung, N. V. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.11.030 · Cited by 154
Role of natural killer cells in cancer.
Pross, H. F., & Lotzová, E. (1994) · PubMed · Cited by 151
von Strandmann, E. P., Hansen, H. P., Reiners, K. S., Schnell, R., Borchmann, P., Merkert, S., Simhadri, V. R., Draube, A., Reiser, M., Purr, I., et al. (2005) · Blood · doi:10.1182/blood-2005-05-2177 · Cited by 147
Li, L., Liu, L. N., Feller, S., Allen, C., Shivakumar, R., Fratantoni, J. C., Wolfraim, L. A., Fujisaki, H., Campana, D., Chopas, N., et al. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.61 · Cited by 144
Low natural-killer-cell activity in familial melanoma patients and their relatives
Hersey, P., Edwards, A. M., Honeyman, M. C., & McCarthy, W. H. (1979) · British Journal of Cancer · doi:10.1038/bjc.1979.147 · Cited by 143
Zhang, T., Wu, M.-R., & Sentman, C. L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103495 · Cited by 141
Li, Y., Wang, Q., & Mariuzza, R. A. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20102548 · Cited by 133
Soluble NKG2D ligands: prevalence, release, and functional impact
Salih, H. R., Holdenrieder, S., & Steinle, A. (2008) · Frontiers in bioscience · doi:10.2741/2939 · Cited by 133
Baessler, T., Charton, J. E., Schmiedel, B. J., Grünebach, F., Krusch, M., Wacker, A., Rammensee, H., & Salih, H. R. (2009) · Blood · doi:10.1182/blood-2009-06-227934 · Cited by 128
Prospects for TIM3-Targeted Antitumor Immunotherapy
Ngiow, S. F., Teng, M. W. L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1487 · Cited by 128
Alvarez, I. B., Pasquinelli, V., Jurado, J. O., Abbate, E. H., Musella, R. M., de la Barrera, S., & García, V. (2010) · The Journal of Infectious Diseases · doi:10.1086/654932 · Cited by 122
Jing, W., Gershan, J. A., Weber, J. J., Tlomak, D., McOlash, L., Sabatos-Peyton, C. A., & Johnson, B. D. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0043-z · Cited by 121
Shahied, L., Tang, Y., Alpaugh, R. K., Somer, R. A., Greenspon, D., & Weiner, L. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407888200 · Cited by 120
PD-1 Expression on Natural Killer Cells and CD8 + T Cells During Chronic HIV-1 Infection
Norris, S., Coleman, A., Kuri-Cervantes, L., Bower, M., Nelson, M. R., & Goodier, M. R. (2012) · Viral Immunology · doi:10.1089/vim.2011.0096 · Cited by 117
Lehner, M., Götz, G., Proff, J., Schaft, N., Dörrie, J., Full, F., Ensser, A., Muller, Y. A., Cerwenka, A., Abken, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031210 · Cited by 111
NKG2D CARs as Cell Therapy for Cancer
Sentman, C. L., & Meehan, K. R. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000029 · Cited by 111
Regulation of perforin‐independent NK cell‐mediated cytotoxicity
Wallin, R. P. A., Screpanti, V., Michaëlsson, J., Grandien, A., & Ljunggren, H. (2003) · European Journal of Immunology · doi:10.1002/eji.200324070 · Cited by 108
Role of Natural Killer Cells in Tumor Growth and Metastasis: C57BL/6 Normal and Beige Mice 2 3
Talmadge, J. E., Meyers, K. M., Prieur, D. J., et al. (1980) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/65.5.929 · Cited by 108
Wada, H., Matsumoto, N., Maenaka, K., Suzuki, K., & Yamamoto, K. (2003) · European Journal of Immunology · doi:10.1002/eji.200324432 · Cited by 105
Vallera, D. A., Zhang, B., Gleason, M., Oh, S., Weiner, L. M., Kaufman, D. S., McCullar, V., Miller, J. S., & Verneris, M. R. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1329 · Cited by 105
GITR Ligand Provided by Thrombopoietic Cells Inhibits NK Cell Antitumor Activity
Placke, T., Salih, H. R., & Kopp, H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103194 · Cited by 104
IL-15 Superagonist–Mediated Immunotoxicity: Role of NK Cells and IFN-γ
Guo, Y., Luan, L., Rabacal, W., Bohannon, J. K., Fensterheim, B. A., Hernandez, A., & Sherwood, E. R. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500300 · Cited by 103
Barber, A., Rynda, A., & Sentman, C. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902000 · Cited by 103
Tumor growth impedes natural-killer-cell maturation in the bone marrow
Richards, J. O., Chang, X., Blaser, B. W., Caligiuri, M. A., Zheng, P., & Liu, Y. (2006) · Blood · doi:10.1182/blood-2005-11-4535 · Cited by 99
Eguizábal, C., Zenarruzabeitia, O., Monge, J., Santos, S. D. M., Vesga, M. Á., Maruri, N., Arrieta, A., n, M. R., Tamayo-Orbegozo, E., Amo, L., et al. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00439 · Cited by 99
Hartmann, F., Renner, C., Jung, W. E., Costa, L. M. D., Tembrink, S., Held, G., Sek, A., König, J., Bauer, S., Kloft, M., et al. (2001) · PubMed · Cited by 99
Elboim, M., Gazit, R., Gur, C., Ghadially, H., Betser-Cohen, G., & Mandelboim, O. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901644 · Cited by 96
Modulation of Natural Killer Cell Anti-Tumor Reactivity by Platelets
Placke, T., Kopp, H., & Salih, H. R. (2011) · Journal of Innate Immunity · doi:10.1159/000323936 · Cited by 83
Enhancement of NK cell antitumor responses using an oncolytic parvovirus
Bhat, R., Dempe, S., Dinsart, C., & Rommelaere, J. (2010) · International Journal of Cancer · doi:10.1002/ijc.25415 · Cited by 79
Singer, H., Kellner, C., Lanig, H., Aigner, M., Stockmeyer, B., Oduncu, F. S., Schwemmlein, M., Stein, C., Mentz, K., Mackensen, A., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181dda225 · Cited by 78
VanSeggelen, H., Hammill, J. A., Dvorkin‐Gheva, A., Tantalo, D. G. M., Kwiecień, J. M., Denisova, G. F., Rabinovich, B. A., Wan, Y., & Bramson, J. L. (2015) · Molecular Therapy · doi:10.1038/mt.2015.119 · Cited by 76
Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions
Battella, S., Cox, M. C., Santoni, A., & Palmieri, G. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr0415-141r · Cited by 71
Retargeting NK‐92 for anti‐melanoma activity by a TCR‐like single‐domain antibody
Zhang, G., Liu, R., Zhu, X., et al. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.45 · Cited by 69
Liu, H., Yang, B. Y., Sun, T., Lin, L., Hu, Y., Deng, M., Yang, J., Liu, T., Li, J., Sun, S., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3548 · Cited by 68
Effects of Peptide on NK Cell-Mediated MHC I Recognition
Cassidy, S. A., Cheent, K. S., & Khakoo, S. I. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00133 · Cited by 67
Familial occurrence of breast cancer is associated with reduced natural killer cytotoxicity
Strayer, D. R., Carter, W. A., & Brodsky, I. (1986) · Breast Cancer Research and Treatment · doi:10.1007/bf01806249 · Cited by 66
Sun, H., Sun, C., & Xiao, W. (2013) · Cytokine · doi:10.1016/j.cyto.2013.09.016 · Cited by 65
Zhang, T., & Sentman, C. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3200 · Cited by 65
IL-15-Induced IL-10 Increases the Cytolytic Activity of Human Natural Killer Cells
Park, J. Y., Lee, S. H., Yoon, S. R., Park, Y., Jung, H., Kim, T., & Choi, I. (2011) · Molecules and Cells · doi:10.1007/s10059-011-1057-8 · Cited by 64
Pluripotent stem cell-derived natural killer cells for cancer therapy
Knorr, D. A., & Kaufman, D. S. (2010) · Translational research · doi:10.1016/j.trsl.2010.07.008 · Cited by 62
Rothe, A., Jachimowicz, R. D., Borchmann, S., Madlener, M., Keßler, J., Reiners, K. S., Sauer, M., Hansen, H. P., Ullrich, R. T., Chatterjee, S., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28609 · Cited by 60
The Chemokine System in Experimental and Clinical Hematology
Bruserud, Ø., & Kittang, A. O. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_18 · Cited by 52
Expression of Ligands to NKp46 in Benign and Malignant Melanocytes
Cagnano, E., Hershkovitz, O., Zilka, A., Bar-Ilan, A., Golder, A., Sion‐Vardy, N., Bogdanov‐Berezovsky, A., Mandelboim, O., Benharroch, D., & Porgador, A. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701111 · Cited by 51
Bruenke, J., Fischer, B. E., Barbin, K., Schreiter, K., Wachter, Y., Mahr, K., Titgemeyer, F., Niederweis, M., Peipp, M., Zunino, S. J., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04893.x · Cited by 51
Kellner, C., Bruenke, J., Horner, H., Schubert, J. E. A., Schwenkert, M., Mentz, K., Barbin, K., Stein, C., Peipp, M., & Stockmeyer, B. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.020 · Cited by 47
Tripathy, S. K., Smith, H. R. C., Holroyd, E. A., Pingel, J. T., & Yokoyama, W. M. (2005) · Journal of Virology · doi:10.1128/jvi.80.1.545-550.2006 · Cited by 47
Vahlne, G., Lindholm, K., Meier, A., Wickström, S. L., Lakshmikanth, T., Brennan, F. R., Wilken, M., Nielsen, R., Romagné, F., Wagtmann, N. R., et al. (2009) · European Journal of Immunology · doi:10.1002/eji.200939755 · Cited by 38
Asano, R., Nakayama, M., Kawaguchi, H., Kubota, T., Nakanishi, T., Umetsu, M., Hayashi, H., Katayose, Y., Unno, M., Kudo, T., et al. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08417.x · Cited by 33
Placke, T., Kopp, H., & Salih, H. R. (2012) · OncoImmunology · doi:10.4161/onci.19367 · Cited by 33
An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities
Tal, Y., Yaakobi, S., Horovitz‐Fried, M., Safyon, E., Rosental, B., Porgador, A., & Cohen, C. J. (2014) · Oncotarget · doi:10.18632/oncotarget.1919 · Cited by 30
Cytokine treatment in cancer immunotherapy
Ardolino, M., Hsu, J., & Raulet, D. H. (2015) · Oncotarget · doi:10.18632/oncotarget.5095 · Cited by 26
Kasuya (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000332 · Cited by 14
To kill, you have to duck an HDAC
Altman, A., & Kong, K. (2011) · Nature Immunology · doi:10.1038/ni0411-279 · Cited by 4
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 747
Cancer immunotherapy: Pros, cons and beyond
Tan, S., Li, D., & Zhu, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109821 · Cited by 688
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553
Metadata
- Authors
- Morvan, M. G., & Lanier, L. L.
- Venue
- Nature Reviews Cancer
- Published
- 2015-12-23
- Volume
- 16
- Issue
- 1
- Pages
- 7-19
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2221432805
- Cited by
- 1,162
- References
- 179
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.